Richter MD, et al. - Authors pursued this research in order to gauge the risk of rheumatologic disease flare and adverse effects in patients with preexisting rheumatologic disease receiving checkpoint inhibitor therapy. No substantial variations were brought to light with regard to time from cancer diagnosis to immunotherapy, duration of immunotherapy, age, or sex between the patients with and without Immune-related adverse effects (IRAEs). It was discovered that only a minority of the patients experienced a flare of their preexisting rheumatologic disease or any other IRAE.